Polivy combo approved by EC as first-line DLBCL treatment
Roche (ROG: SIX) has won approval from the European Commission (EC) for the use of Polivy (polatuzumab vedotin) in combination with MabThera (rituximab) plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adults with untreated diffuse large B-cell lymphoma (DLBCL).
Polivy is being developed by the Swiss pharma giant using Seagen’s (Nasdaq: SGEN) ADC technology and is currently being investigated for the treatment of several types of non-Hodgkin lymphoma (NHL).
"A new era for people battling this aggressive disease"DLBCL is an aggressive blood cancer and the most common form of NHL. Each year in Europe, it is estimated that 40,000 people are diagnosed with DLBCL. While many patients are responsive to initial treatment, four out of 10 are not cured with the current standard of care, and the majority of people who require subsequent lines of therapy have poor outcomes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze